Stocksigma LogoStocksigma Logo

Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan for JPY 21.5 Billion

Gujarat Themis Biosyn completed the 100% acquisition of MicroBiopharm Japan on 18th Sep'26 via its subsidiary, Themis Biosyn Japan, for JPY 21.5 billion

Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan for JPY 21.5 Billion

Gujarat Themis Biosyn Ltd 路 Others (Uncategorized) 路 18 Sept 2026, 4:01 pm

Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan for JPY 21.5 Billion Gujarat Themis Biosyn completed the 100% acquisition of MicroBiopharm Japan on 18th Sep'26 via its subsidiary, Themis Biosyn Japan, for JPY 21.5 billion, funded via INR 475 crore equity and an INR 745 crore loan. The transaction is expected to be EPS accretive. MBJ registered FY26 revenue of JPY 9.5 billion across proprietary APIs, CDMO, and biologics, with ~40% derived outside Japan across three GMP-compliant plants. The acquisition expands GTBL鈥檚 precision fermentation capabilities, novel modalities, and global CDMO reach.

Original exchange filing (PDF)

More announcements from Gujarat Themis Biosyn Ltd

All Gujarat Themis Biosyn Ltd announcements